Biotech Regeneron’s Yancopoulos is still bitter over Praluent sales. Can Novartis do better? By Adam Feuerstein @adamfeuerstein
January 15, 2020
Kristoffer Tripplaar/Sipa via AP
S AN FRANCISCO — George Yancopoulos, Regeneron Pharma’s top scientist, is still a bit bitter about the commercial flop of its cholesterol-lowering PCSK9 inhibitor Praluent. At an event on the sidelines of J.P. Morgan Healthcare Conference on Tuesday, he also threw a tiny bit of shade at Novartis, which believes it can do better with a longer-acting PCSK9 inhibitor it acquired through the $10 billion buyout of The Medicines Company.
Speaking at an event organized by Medicxi Partners, Yancopoulos touted Regeneron’s ability to develop drugs at a rate much higher than the industry average, but “a drug like Praluent should have been available to tens of millions of people.”
Unlock this article by subscribing to STAT Plus. To get you started, enjoy 50% off your first 3 months!
GET STARTED Log In | Learn More What is it? STAT Plus is STAT's premium subscription service for in-depth biotech, pharma, policy, and life science coverage and analysis. Our award-winning team covers news on Wall Street, policy developments in Washington, early science breakthroughs and clinical trial results, and health care disruption in Silicon Valley and beyond.
What's included? Daily reporting and analysis The most comprehensive industry coverage from a powerhouse team of reporters Subscriber-only newsletters Daily newsletters to brief you on the most important industry news of the day Online intelligence briefings Frequent opportunities to engage with veteran beat reporters and industry experts Exclusive industry events Premium access to subscriber-only networking events around the country The best reporters in the industry The most trusted and well-connected newsroom in the health care industry And much more Exclusive interviews with industry leaders, profiles, and premium tools, like our CRISPR Trackr. GET STARTED
Also in Industry News
How to decide whether or not to start treatment for prostate cancer?
Analysis of the SARS-CoV-2 proteome via visual tools
$65m investment increases British Patient Capital’s exposure to life sciences and health technology